Form 4: BioXcel Therapeutics Executive Javier Rodriguez Reports Stock Sales and RSU Transactions
SEC Form 4
Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, reported the sale of common stock and the vesting of restricted stock units (RSUs) in recent transactions.
Summary
- Javier Rodriguez, a BioXcel Therapeutics executive, filed a Form 4 detailing changes in beneficial ownership.
- On March 14, 2024, 521 shares were acquired through the vesting of Restricted Stock Units (RSUs).
- On March 15, 2024, 2,250 shares were acquired through the vesting of RSUs.
- On April 4, 2024, 1,012 shares were sold at a weighted average price of $2.6358 per share, with prices ranging from $2.625 to $2.654.
- Following these transactions, Rodriguez directly owns 7,672 shares of common stock and 4,169 and 6,750 Restricted Stock Units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions that are part of a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter. |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter. |
| 2023-12-14 | Rule 10b5-1 trading plan adopted by the Reporting Person. |
| 2024-03-14 | 521 shares acquired through RSU vesting. |
| 2024-03-15 | 2,250 shares acquired through RSU vesting. |
| 2024-04-04 | 1,012 shares sold at an average price of $2.6358. |
| 2024-04-08 | Date of Form 4 filing. |
Keywords
Form 4, BioXcel Therapeutics, BTAI, Insider Trading, Javier Rodriguez, Restricted Stock Units, Stock Sale, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.